Brief: Fusen Pharmaceutical Logs HY Loss Attributable RMB13.6 Million
31/08/2026 17:19
BRIEF-Fusen Pharmaceutical Logs HY Loss Attributable RMB13.6 Million Aug 31 (Reuters) - Fusen Pharmaceutical Co Ltd 1652.HK:
LOSS ATTRIBUTABLE TO EQUITY SHAREHOLDERS RMB13.6 MILLION FOR SIX MONTHS ENDED 30 JUNE 2026
REVENUE INCREASED 2.5% TO RMB114.1 MILLION FOR SIX MONTHS ENDED 30 JUNE 2026
DO NOT RECOMMEND THE PAYMENT OF A DIVIDEND IN RESPECT OF THE SIX MONTHS ENDED 30 JUNE 2026
Further company coverage: 1652.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fusen Pharmaceutical
See all newsBrief: Fusen Pharmaceutical Logs HY Loss Attributable RMB13.6 Million
Brief: Fusen Pharmaceutical Says Doxazosin Mesylate Extended-Release Tablets Approved For Marketing In China
Brief: Fusen Pharmaceutical Says Peramivir Injection First Neuraminidase Inhibitor Approved In China For Intravenous Influenza Treatment
Brief: Fusen Pharmaceutical Says Investors To Contribute RMB300 Mln For 34% Stake Subscription Of Henan Fusen Pharmaceutical
Brief: Fusen Pharmaceutical Says Piracetam Injection Approved For Marketing By NMPA